Overview

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca